Chemoradiation With or Without Surgery for Stage IIIA Non-Small Cell Lung Cancer (NSCLC): A Comparison of Survival and Patterns of Failure
James Metz, MD
OncoLink Associate Editor
Ultima Vez Modificado: 3 de noviembre del 1999
Presenter: Mitchell Machtay, MD
Affiliation: University of Pennsylvania
One of the most controversial topics in the management of NSCLC is the treatment of stage IIIA disease. Chemotherapy is generally accepted as an indicated treament in patients with good performance status. The management of local disease using surgery versus radiation therapy remains controversial. This study was performed to evaluated outcomes in patients with stage IIIA NSCLC treated with definitive chemoradiation vs preoperative chemoradiation therapy. Materials and Methods:
- Charts of 83 patients with NSCLC were reviewed retrospectively
- 83% had a mediastinoscopy to confirm N2 disease
- All patients received chemoradiation therapy
- The two groups were divided by intended preoperative chemoradiation followed by surgery versus definitive chemoradiation
- 39 patients were treated with a preoperative approach
- Median follow-up in this series is 16 months
- Local-regional control was better in the patients where surgery is planned (81% vs 50%)
- Distant metastatic rate was 49% in both groups
- Overall death from respiratory failure was 33% with no difference between the groups
- Overall survival at 3 years is not different between the 2 groups
- An analysis of the preoperative chemoradiation patients showed 31/39 (77%)underwent surgical resection
- Toxicity and treatment related death was similar in both groups
- There was no difference in survival between the 2 groups
- There was increased local-regional control in the surgical group, although it must be remembered this is a selected group of patients
- It is clear that improvements in systemic control are needed to improve overall survival in patients with stage IIIA NSCLC
- It is recommended that patients continue to be enrolled in RTOG 93-09 protocol to identify the most appropriate treatment for stage IIIA NSCLC
ASTRO coverage is sponsored, in part, by Varian Medical Systems, Inc.
Resection for Lung Cancer May Improve Survival Odds
Mar 6, 2015 - In patients with stage IIIA(N2) non-small cell lung cancer, lung resection, preferably by lobectomy, should be considered in addition to chemotherapy and radiotherapy, according to a study published online July 27 in The Lancet.
Frequently Asked Questions
National Cancer Institute
I Wish You Knew
How cancer patients have changed my life
Blogs and Web Chats
OncoLink Blogs give our readers a chance to react to and comment on key cancer news topics and provides a forum for OncoLink Experts and readers to share opinions and learn from each other.
Frente a un nuevo diagnóstico de cáncer o de cambiar el curso de su tratamiento actual? Deje que nuestro personal de enfermería cáncer que ayudan a pasar!